CVS looks to 2023 after opioids settlement, Medicare rating decline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
'Several De-Risking Events Positive' for CVS Health (CVS) - Mizuho
November 2, 2022 12:58 PM EDTMizuho Securities analyst Ann Hynes reiterated a Buy rating and $120.00 price target on CVS Health (NYSE: CVS) following Q3 results as several de-risking events are positive for the stock.
The analyst commented, "CVS announced 1) good Q3:22 earnings, 2) provided 2023 initial 2023 EPS guidance of -3.5%... More
